• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国国立综合癌症网络(National Comprehensive Cancer Network)的胰腺癌可切除性状态可预测总生存期。

National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival.

作者信息

Murakami Yoshiaki, Satoi Sohei, Sho Masayuki, Motoi Fuyuhiko, Matsumoto Ippei, Kawai Manabu, Honda Goro, Uemura Kenichiro, Yanagimoto Hiroaki, Shinzeki Makoto, Kurata Masanao, Kinoshita Shoichi, Yamaue Hiroki, Unno Michiaki

机构信息

Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan,

出版信息

World J Surg. 2015 Sep;39(9):2306-14. doi: 10.1007/s00268-015-3096-3.

DOI:10.1007/s00268-015-3096-3
PMID:26013206
Abstract

BACKGROUND

The aim of this study was to evaluate the validity of preoperative resectability status, as defined by the National Comprehensive Cancer Network (NCCN), from the viewpoint of overall survival.

METHODS

A total of consecutive 704 patients with pancreatic head carcinoma who underwent pancreatoduodenectomy with upfront surgery at seven Japanese hospitals between 2001 and 2012 were evaluated retrospectively. According to the NCCN definition of preoperative resectability status, tumors were divided into resectable tumors without vascular contact (R group), resectable tumors with portal or superior mesenteric vein (PV/SMV) contact of ≦180° (R-PV group), borderline resectable(BR) tumors with PV/SMV contact of >180° (BR-PV group), and BR tumors with arterial contact (BR-A group). The relationship between the NCCN definition of preoperative resectability status and overall survival was analyzed.

RESULTS

Of the 704 patients, 389, 114, 145, and 56 were classified into the R group, the R-PV group, the BR-PV group, and the BR-A group, respectively. Overall survival of the BR-PV and BR-A groups was significantly worse than that of the R group and R-PV groups (P < 0.05), although there was no significant difference in overall survival between the R group and the R-PV group (P = 0.310). Multivariate analysis revealed that PV/SMV contact of >180° (P = 0.008) and arterial contact (P < 0.001) were independent prognostic factors of overall survival.

CONCLUSION

From the viewpoint of overall survival, the NCCN definition of preoperative resectability status was valid.

摘要

背景

本研究旨在从总生存期的角度评估美国国立综合癌症网络(NCCN)所定义的术前可切除性状态的有效性。

方法

对2001年至2012年间在日本七家医院接受一期胰十二指肠切除术的704例连续性胰头癌患者进行回顾性评估。根据NCCN术前可切除性状态的定义,肿瘤分为无血管侵犯的可切除肿瘤(R组)、门静脉或肠系膜上静脉(PV/SMV)侵犯角度≤180°的可切除肿瘤(R-PV组)、PV/SMV侵犯角度>180°的边缘可切除(BR)肿瘤(BR-PV组)以及有动脉侵犯的BR肿瘤(BR-A组)。分析NCCN术前可切除性状态定义与总生存期之间的关系。

结果

704例患者中,分别有389例、114例、145例和56例被归入R组、R-PV组、BR-PV组和BR-A组。BR-PV组和BR-A组的总生存期显著低于R组和R-PV组(P<0.05),尽管R组和R-PV组的总生存期无显著差异(P=0.310)。多因素分析显示,PV/SMV侵犯角度>180°(P=0.008)和动脉侵犯(P<0.001)是总生存期的独立预后因素。

结论

从总生存期的角度来看,NCCN术前可切除性状态的定义是有效的。

相似文献

1
National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival.美国国立综合癌症网络(National Comprehensive Cancer Network)的胰腺癌可切除性状态可预测总生存期。
World J Surg. 2015 Sep;39(9):2306-14. doi: 10.1007/s00268-015-3096-3.
2
Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.重新评估门静脉-肠系膜上静脉侵犯在临界可切除胰腺癌中的临床意义。
Eur J Surg Oncol. 2017 Jun;43(6):1068-1075. doi: 10.1016/j.ejso.2017.03.020. Epub 2017 Apr 8.
3
Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma.门静脉或肠系膜上静脉切除联合辅助化疗治疗胰头癌患者的获益。
J Surg Oncol. 2013 Mar;107(4):414-21. doi: 10.1002/jso.23229. Epub 2012 Aug 6.
4
Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series.胰头伴门静脉受侵的胰腺癌真的是临界可切除吗?一项术前手术系列的评估。
Ann Surg Oncol. 2017 Sep;24(9):2752-2761. doi: 10.1245/s10434-017-5972-6. Epub 2017 Jul 6.
5
Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.胰头癌胰十二指肠切除术中门静脉-肠系膜上静脉切除的临床意义。
Pancreas. 2012 Jan;41(1):102-6. doi: 10.1097/MPA.0b013e318221c595.
6
Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma.胰头癌胰十二指肠切除术中门静脉或肠系膜上静脉切除。
Br J Surg. 2015 Jun;102(7):837-46. doi: 10.1002/bjs.9799. Epub 2015 Apr 15.
7
Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer.肿瘤与门静脉-肠系膜上静脉接触长度对胰腺癌手术患者的预后作用。
Br J Surg. 2019 Nov;106(12):1649-1656. doi: 10.1002/bjs.11328. Epub 2019 Oct 18.
8
Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.胰头腺癌门静脉肠系膜静脉侵犯的长期预后及预后因素
ANZ J Surg. 2015 Apr;85(4):264-9. doi: 10.1111/ans.12502. Epub 2014 Feb 12.
9
Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.胰头导管腺癌伴门静脉肠系膜静脉侵犯整块切除术的长期结果。
Asian J Surg. 2021 Jan;44(1):313-320. doi: 10.1016/j.asjsur.2020.07.021. Epub 2020 Sep 21.
10
Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection.胰腺癌门静脉受累对手术切除后转移模式的影响。
Ann Surg Oncol. 2016 Dec;23(Suppl 5):730-736. doi: 10.1245/s10434-016-5515-6. Epub 2016 Aug 23.

引用本文的文献

1
Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information.基于术前和术后基因组信息对胰腺导管腺癌患者的预后进行精确分层。
Cancer Cell Int. 2025 Aug 18;25(1):305. doi: 10.1186/s12935-025-03894-9.
2
Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study.胰十二指肠切除术后胰腺癌局部复发相关的危险因素和血管特征:一项回顾性队列研究
Cancer Rep (Hoboken). 2025 Jul;8(7):e70267. doi: 10.1002/cnr2.70267.
3
A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors.

本文引用的文献

1
Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).交界可切除胰腺癌:国际胰腺外科研究组(ISGPS)的共识声明。
Surgery. 2014 Jun;155(6):977-88. doi: 10.1016/j.surg.2014.02.001. Epub 2014 Feb 7.
2
Cancer statistics, 2014.癌症统计数据,2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
3
Borderline resectable/locally advanced pancreatic adenocarcinoma: improvements needed in population-based registries.
胃肠道肿瘤免疫治疗的全面综述,重点关注与PARP抑制剂联合治疗的作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 9. doi: 10.1007/s00210-025-04336-z.
4
Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer.用于预测胰腺癌新辅助治疗后R状态的贝叶斯模型
Cancers (Basel). 2024 Dec 7;16(23):4106. doi: 10.3390/cancers16234106.
5
Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer.36 例胰腺癌类器官的建立、鉴定及建库:可切除胰腺癌转移的预测。
Cell Oncol (Dordr). 2024 Oct;47(5):1627-1647. doi: 10.1007/s13402-024-00939-5. Epub 2024 Apr 15.
6
Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement.全新辅助治疗可提高伴有动脉受累的可切除边缘性胰腺癌患者的生存率。
Ann Gastroenterol Surg. 2023 Aug 10;8(1):151-162. doi: 10.1002/ags3.12726. eCollection 2024 Jan.
7
Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival.胰头癌毗邻脾门时更有可能侵犯脾血管,且生存预后不良。
Langenbecks Arch Surg. 2023 Sep 11;408(1):353. doi: 10.1007/s00423-023-03089-8.
8
ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma.
Ann Surg Oncol. 2023 Dec;30(13):8644-8645. doi: 10.1245/s10434-023-14261-1. Epub 2023 Sep 10.
9
Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas.术前肿瘤大小对可切除和交界可切除胰腺导管腺癌预后的影响。
Ann Surg Oncol. 2023 Dec;30(13):8621-8630. doi: 10.1245/s10434-023-14219-3. Epub 2023 Sep 1.
10
Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer.可切除或临界可切除胰腺癌围手术期治疗的当前价值
Yonago Acta Med. 2023 May 10;66(2):202-207. doi: 10.33160/yam.2023.05.014. eCollection 2023 May.
交界可切除/局部进展期胰腺腺癌:基于人群的登记处需要改进。
Ann Surg Oncol. 2013 Dec;20(13):4338-47. doi: 10.1245/s10434-013-3237-6. Epub 2013 Sep 4.
4
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.一项多机构的 II 期研究,评估新辅助吉西他滨和奥沙利铂联合放化疗治疗胰腺癌患者的疗效。
Cancer. 2013 Aug 1;119(15):2692-700. doi: 10.1002/cncr.28117. Epub 2013 May 29.
5
Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines.边缘可切除胰腺癌的积极手术:国家综合癌症网络指南评估。
Pancreas. 2013 Aug;42(6):1004-10. doi: 10.1097/MPA.0b013e31827b2d7c.
6
Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery.可切除边缘性胰头/体部癌的临床特征及治疗结果:日本胰腺外科学会的多机构调查
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):601-10. doi: 10.1007/s00534-013-0595-1.
7
Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma.门静脉或肠系膜上静脉切除联合辅助化疗治疗胰头癌患者的获益。
J Surg Oncol. 2013 Mar;107(4):414-21. doi: 10.1002/jso.23229. Epub 2012 Aug 6.
8
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.新辅助吉西他滨联合卡培他滨化疗治疗局部进展期或不可切除的边界可切除胰腺癌的前瞻性疗效和安全性研究。
Surgery. 2012 Nov;152(5):851-62. doi: 10.1016/j.surg.2012.03.010. Epub 2012 Jun 6.
9
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.边缘可切除胰腺癌对新辅助治疗的反应不能通过影像学指标反映。
Cancer. 2012 Dec 1;118(23):5749-56. doi: 10.1002/cncr.27636. Epub 2012 May 17.
10
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.胰腺癌手术后吉西他滨加 S-1 辅助化疗的长期结果。
J Surg Oncol. 2012 Aug 1;106(2):174-80. doi: 10.1002/jso.23068. Epub 2012 Feb 13.